ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Genentech will work with New York City-based Lodo Therapeutics to mine bacterial genomes for novel natural products. Deal specifics were not disclosed, but Lodo could get up to $969 million as projects progress. Lodo, which was one of C&EN’s 10 Start-ups to Watch in 2016, is based on methods developed by its cofounder, Rockefeller University chemist Sean Brady. His group searches bacterial genomes for gene clusters that encode for unique molecules with specific properties.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter